When Zamann Pharma Support started working with a German pharmaceutical manufacturer, the request initially focused on improving compliance with FDA and EMA requirements for Equipment Qualification.
However, after deeper analysis, a critical issue became visible. In reality, the core problem was not the qualification system itself. Instead, the organization continuously implemented changes on already qualified equipment without properly evaluating their impact on the validated state.
For example, software updates were installed, critical components were replaced, parameters were adjusted, and vendors performed maintenance corrections. Nevertheless, none of these changes triggered impact assessments, requalification activities, or even proper documentation.
As a result, the qualification status was silently compromised, even though documentation still appeared compliant. Therefore, this represents a serious GMP failure because regulators repeatedly highlight poor change control as a systemic issue that leads to escalation actions, remediation programs, and warning letters.
Our team supports the planning, execution, and maintenance of qualification and validation activities, including IQ, OQ, and PQ, to keep GMP-regulated systems compliant and under control.
A change invalidates the qualified state when it affects critical performance, control logic, or process parameters. Therefore, if the change alters validated conditions without a formal impact assessment, qualification cannot remain valid. In practice, software updates, sensor replacements, or cleaning cycle modifications frequently trigger this risk. As a result, teams must evaluate every change before implementation.
Regulators classify missing impact assessments as critical because they eliminate visibility over how changes affect system performance and product quality. Consequently, companies cannot demonstrate that validated conditions still exist. Moreover, without documented evaluation, QA cannot justify continued operation. As a result, this gap often leads to FDA 483 observations and EMA inspection findings.
Changes require requalification when they influence accuracy, control, or process outcomes. For example, firmware updates, component substitutions, parameter adjustments, and cleaning or sterilization modifications directly impact system behavior. Therefore, each change must be assessed against qualification criteria. If necessary, teams must trigger OQ or PQ to confirm continued compliance. Otherwise, the validated state cannot be justified.
